July 26, 2024 07:00 AM EDTUpdated 08:15 AM
Pharma
FDA+

FDA ap­proves Sun Phar­ma's JAK in­hibitor Leq­selvi for hair loss in adults

Katherine Lewin

News Reporter

Sun Phar­ma’s $576 mil­lion ac­qui­si­tion of Con­cert Phar­ma­ceu­ti­cals is pay­ing off with an FDA ap­proval of the alope­cia drug that came with the 2023 deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times